GLP1R and type 2 diabetes mellitus: Plasma endotrophin was determined in samples which had been obtained in a multicentre, open-label, randomised trial, which compared the 52-week treatment with the glucagon-like peptide-1 receptor agonist, dulaglutide, to insulin glargine in 329 patients with type 2 diabetes and moderate-to-severe chronic kidney disease33.